These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 23117174)

  • 1. 5-(1,3-Benzothiazol-6-yl)-4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazole derivatives as potent and selective transforming growth factor-β type I receptor inhibitors.
    Amada H; Sekiguchi Y; Ono N; Koami T; Takayama T; Yabuuchi T; Katakai H; Ikeda A; Aoki M; Naruse T; Wada R; Nozoe A; Sato M
    Bioorg Med Chem; 2012 Dec; 20(24):7128-38. PubMed ID: 23117174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and evaluation of novel 4-thiazolylimidazoles as inhibitors of transforming growth factor-β type I receptor kinase.
    Amada H; Sekiguchi Y; Ono N; Matsunaga Y; Koami T; Asanuma H; Shiozawa F; Endo M; Ikeda A; Aoki M; Fujimoto N; Wada R; Sato M
    Bioorg Med Chem Lett; 2012 Mar; 22(5):2024-9. PubMed ID: 22325945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of 7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole (TASP0382088): a potent and selective transforming growth factor-β type I receptor inhibitor as a topical drug for alopecia.
    Amada H; Asanuma H; Koami T; Okada A; Endo M; Ueda Y; Naruse T; Ikeda A
    Chem Pharm Bull (Tokyo); 2013; 61(3):286-91. PubMed ID: 23449197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of 1,2,4-trisubstituted imidazoles as inhibitors of transforming growth factor-β type I receptor (ALK5).
    Guo C; Zhang C; Li X; Li W; Xu Z; Bao L; Ding Y; Wang L; Li S
    Bioorg Med Chem Lett; 2013 Nov; 23(21):5850-4. PubMed ID: 24055046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel ALK5 inhibitor TP0427736 reduces TGF-β　induced growth inhibition in human outer root sheath cells and elongates anagen phase in mouse hair follicles.
    Naruse T; Aoki M; Fujimoto N; Arase S; Oura H; Ueda Y; Ikeda A
    Pharmacol Rep; 2017 Jun; 69(3):485-491. PubMed ID: 28324846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis.
    Grygielko ET; Martin WM; Tweed C; Thornton P; Harling J; Brooks DP; Laping NJ
    J Pharmacol Exp Ther; 2005 Jun; 313(3):943-51. PubMed ID: 15769863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of 2-benzylamino-4(5)-(6-methylpyridin-2-yl)-5(4)-([1,2,4]triazolo[1,5-a]-pyridin-6-yl)thiazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
    Krishnaiah M; Jin CH; Sreenu D; Subrahmanyam VB; Rao KS; Son DH; Park HJ; Kim SW; Sheen YY; Kim DK
    Eur J Med Chem; 2012 Nov; 57():74-84. PubMed ID: 23047226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of 4(5)-(6-methylpyridin-2-yl)imidazoles and -pyrazoles as transforming growth factor-beta type 1 receptor kinase inhibitors.
    Kim DK; Lee YI; Lee YW; Dewang PM; Sheen YY; Kim YW; Park HJ; Yoo J; Lee HS; Kim YK
    Bioorg Med Chem; 2010 Jun; 18(12):4459-67. PubMed ID: 20472445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5(3)-(6-methylpyridin-2-yl)imidazole and -pyrazole derivatives as potent and selective inhibitors of transforming growth factor-β type I receptor kinase.
    Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Park HJ; Park SJ; Sheen YY; Kim DK
    Bioorg Med Chem; 2014 May; 22(9):2724-32. PubMed ID: 24704197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of benzenesulfonamide-substituted 4-(6-alkylpyridin-2-yl)-5-(quinoxalin-6-yl)imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors.
    Kim DK; Jung SH; Lee HS; Dewang PM
    Eur J Med Chem; 2009 Feb; 44(2):568-76. PubMed ID: 18467006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung.
    Park CY; Son JY; Jin CH; Nam JS; Kim DK; Sheen YY
    Eur J Cancer; 2011 Nov; 47(17):2642-53. PubMed ID: 21852112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of 1,2,4-trisubstituted imidazoles and 1,3,5-trisubstituted pyrazoles as inhibitors of transforming growth factor beta type 1 receptor (ALK5).
    Li X; Wang L; Long L; Xiao J; Hu Y; Li S
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4868-72. PubMed ID: 19616940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and evaluation of small molecule imidazo[2,1-b][1,3,4]thiadiazoles as inhibitors of transforming growth factor-β type-I receptor kinase (ALK5).
    Patel HM; Sing B; Bhardwaj V; Palkar M; Shaikh MS; Rane R; Alwan WS; Gadad AK; Noolvi MN; Karpoormath R
    Eur J Med Chem; 2015 Mar; 93():599-613. PubMed ID: 25234355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of 4(5)-(6-alkylpyridin-2-yl)imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors.
    Kim DK; Jang Y; Lee HS; Park HJ; Yoo J
    J Med Chem; 2007 Jun; 50(13):3143-7. PubMed ID: 17552507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7.
    DaCosta Byfield S; Major C; Laping NJ; Roberts AB
    Mol Pharmacol; 2004 Mar; 65(3):744-52. PubMed ID: 14978253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
    Jin CH; Sreenu D; Krishnaiah M; Subrahmanyam VB; Rao KS; Nagendra Mohan AV; Park CY; Son JY; Son DH; Park HJ; Sheen YY; Kim DK
    Eur J Med Chem; 2011 Sep; 46(9):3917-25. PubMed ID: 21696866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of 1-(6-methylpyridin-2-yl)-5-(quinoxalin-6-yl)-1,2,3-triazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
    Li F; Park Y; Hah JM; Ryu JS
    Bioorg Med Chem Lett; 2013 Feb; 23(4):1083-6. PubMed ID: 23294702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of 1-substituted-3-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
    Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Rao KS; Mohan AV; Park CY; Son JY; Sheen YY; Kim DK
    Bioorg Med Chem Lett; 2011 Oct; 21(20):6049-53. PubMed ID: 21911290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of 2-pyridyl-substituted pyrazoles and imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors.
    Dewang PM; Kim DK
    Bioorg Med Chem Lett; 2010 Jul; 20(14):4228-32. PubMed ID: 20621731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinolin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
    Jin CH; Krishnaiah M; Sreenu D; Rao KS; Subrahmanyam VB; Park CY; Son JY; Sheen YY; Kim DK
    Bioorg Med Chem; 2011 Apr; 19(8):2633-40. PubMed ID: 21435890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.